HUTCHMED
About: HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Employees: 1,811
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1% more capital invested
Capital invested by funds: $98.1M [Q4 2024] → $98.6M (+$553K) [Q1 2025]
0.03% less ownership
Funds ownership: 0.78% [Q4 2024] → 0.75% (-0.03%) [Q1 2025]
9% less funds holding
Funds holding: 67 [Q4 2024] → 61 (-6) [Q1 2025]
26% less call options, than puts
Call options by funds: $149K | Put options by funds: $202K
43% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 30
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for HCM.
Financial journalist opinion
Based on 4 articles about HCM published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 week ago
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (“TKI”) has been accepted for review by the China National Medical Products Administration (“NMPA”).
Neutral
GlobeNewsWire
2 weeks ago
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —
Neutral
GlobeNewsWire
3 weeks ago
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA.
Neutral
GlobeNewsWire
1 month ago
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois.
Positive
Proactive Investors
1 month ago
HUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestone
Shares in Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013) rose 10% in early trading on Tuesday after the biopharma company announced it had completed patient enrolment for a key phase II trial of its cancer drug savolitinib in China. The study is testing the treatment in people with gastric or gastroesophageal junction cancer whose tumours show MET gene amplification - a relatively rare but aggressive subtype.
Neutral
GlobeNewsWire
1 month ago
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification.
Negative
Zacks Investment Research
2 months ago
3 Internet Delivery Services Stocks in Focus Amid Industry Challenges
Tariff war, inflationary pressure and still-high interest rates are major concerns for the Zacks Internet - Delivery Services industry. However, efforts to adopt consumer preferences and technological advancements are likely to help GDDY, QNST and ASUR navigate the headwinds.
Neutral
GlobeNewsWire
2 months ago
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED's fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) with EZH2 mutation who have received at least two prior systemic therapies.
Neutral
GlobeNewsWire
2 months ago
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors of the Company for more than eight years, have informed the Company that they would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 13, 2025 (“AGM”).
Charts implemented using Lightweight Charts™